BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ALTO-100 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ALTO-100\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06656416-804@assetmemo.bio
DTSTAMP:20261121T004945Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:ALTO-100: Phase 2 readout est. (NCT06656416)
DESCRIPTION:ALTO-100\, phase 2\, Bipolar Disorder.\nStudy: ALTO-100 in Bipo
 lar Disorder With Depression (BD-D)\nEstimated primary completion: Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/alto-100#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0665641
 6
URL:https://assetmemo.bio/drug/alto-100#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
